Olapag
Generic Name
Olaparib
Manufacturer
Generic Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olapag 50 mg tablet | ৳ 900.00 | ৳ 9,000.00 |
Description
Overview of the medicine
Olaparib is an oral poly(ADP-ribose) polymerase (PARP) inhibitor used for the treatment of certain cancers, including ovarian, breast, pancreatic, and prostate cancers, often in patients with BRCA gene mutations.
Uses & Indications
Dosage
Adults
Recommended dose is 300 mg (six 50 mg tablets) twice daily, equivalent to 600 mg total daily dose.
Elderly
No specific dosage adjustment required based on age alone, but monitor renal function.
Renal_impairment
Mild renal impairment (CrCl 51-80 mL/min) no adjustment. Moderate renal impairment (CrCl 31-50 mL/min): 200 mg (four 50 mg tablets) twice daily. Severe renal impairment (CrCl <30 mL/min) not studied.
How to Take
Oral administration, take with or without food. Swallow tablets whole, do not chew, crush, or split.
Mechanism of Action
Olaparib inhibits PARP enzymes (PARP-1, PARP-2, and PARP-3), which play a key role in DNA repair. By inhibiting PARP, Olaparib traps PARP at DNA damage sites, leading to synthetic lethality in cancer cells with homologous recombination repair (HRR) deficiencies (e.g., BRCA1/2 mutations).
Pharmacokinetics
Onset
Not explicitly defined in terms of immediate clinical effect, but systemic exposure occurs rapidly.
Excretion
Primarily excreted via urine (44%) and feces (42%), with less than 2% as unchanged drug.
Half life
Terminal elimination half-life is 15-17 hours.
Absorption
Rapidly absorbed, peak plasma concentrations typically reached 1.5 hours after administration. Absolute bioavailability is approximately 59%.
Metabolism
Primarily metabolized by CYP3A4/5.
Side Effects
Contraindications
- Hypersensitivity to Olaparib or any excipients.
Drug Interactions
Strong CYP3A inducers (e.g., rifampicin, phenytoin, St. John's Wort)
Avoid concomitant use or consider alternative agents.
Strong CYP3A inhibitors (e.g., itraconazole, clarithromycin, grapefruit juice)
Avoid concomitant use or reduce Olaparib dose.
Storage
Store below 30°C, protected from moisture. Keep out of reach of children.
Overdose
No specific antidote. In case of overdose, provide supportive care and manage symptoms.
Pregnancy & Lactation
Olaparib can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Use effective contraception during treatment and for 6 months after the last dose. Advise women not to breastfeed during treatment and for 1 month after the last dose.
Side Effects
Contraindications
- Hypersensitivity to Olaparib or any excipients.
Drug Interactions
Strong CYP3A inducers (e.g., rifampicin, phenytoin, St. John's Wort)
Avoid concomitant use or consider alternative agents.
Strong CYP3A inhibitors (e.g., itraconazole, clarithromycin, grapefruit juice)
Avoid concomitant use or reduce Olaparib dose.
Storage
Store below 30°C, protected from moisture. Keep out of reach of children.
Overdose
No specific antidote. In case of overdose, provide supportive care and manage symptoms.
Pregnancy & Lactation
Olaparib can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Use effective contraception during treatment and for 6 months after the last dose. Advise women not to breastfeed during treatment and for 1 month after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months
Availability
Pharmacies, Hospitals
Approval Status
Approved
Patent Status
Patented
Clinical Trials
Extensive clinical trials (e.g., SOLO, PAOLA, PROfound, OlympiAD) have demonstrated efficacy and safety in various indications.
Lab Monitoring
- Complete blood counts (CBC) monthly for the first 12 months, then periodically.
- Renal function tests.
- Liver function tests.
Doctor Notes
- Monitor complete blood counts (CBC) closely throughout treatment, especially during the first 12 months.
- Counsel patients on potential severe adverse events, including MDS/AML and pneumonitis, and advise them to report any new or worsening symptoms promptly.
- Assess renal function prior to initiation of treatment and monitor periodically.
Patient Guidelines
- Take exactly as prescribed.
- Do not chew, crush, or split tablets.
- Report any signs of infection, bleeding, or unusual bruising immediately.
- Avoid grapefruit and Seville oranges and their juices.
Missed Dose Advice
If a dose is missed, take the next scheduled dose at its regular time. Do not take a double dose.
Driving Precautions
May cause fatigue, dizziness, or weakness. Patients should be cautious when driving or operating machinery until they know how the medicine affects them.
Lifestyle Advice
- Maintain good hydration.
- Avoid exposure to sick individuals due to myelosuppression.
- Discuss any planned vaccinations with your doctor.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Olapag Brand
Other medicines available under the same brand name
